Sugemalimab vs placebo after cCRT or sCRT in pts with unresectable stage III NSCLC: final PFS analysis of a phase 3 study

9027: A Protocol Pre-specified Interim Overall Survival (OS) Analysis of GEMSTONE-302: A Phase 3 Study of Sugemalimab versus Placebo plus Platinum-based Chemotherapy (Chemo) as First-line (1L) Treatment for Patients with Metastatic Non-small Cell Lung Cancer

GEMSTONE-201: pre-planned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab in patients with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL)

Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).

A protocol pre specified interim overall survival (OS) analysis of GEMSTONE 302: a phase 3 study of sugemalimab (suge) versus placebo plus platinum based chemotherapy (chemo) as first line (1L) treatment for patients (pts) with metastatic non small cell lung cancer (NSCLC)

GEMSTONE-201: pre-planned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL)

Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first‑in‑human phase 1 trial